GE HealthCare Technologies (GEHC) FY 2025 Annual General Meeting May 28, 2025 10:00 AM ET Speaker0 At GE Healthcare, we believe the future of healthcare has no limits and that it will be defined not by how to treat an illness, but by how to treat the patient. The future of healthcare will combine AI with clinician expertise to create a cohesive view of each patient from millions of points of data. It will use advanced imaging to diagnose in minutes. It will make care more predictive and therapies more preci ...

Nano-X Imaging (NNOX) Q1 2025 Earnings Call May 22, 2025 08:30 AM ET Company Participants Mike Cavanaugh - Managing DirectorErez Meltzer - CEO & Acting Chairman of the BoardRan Daniel - Chief Financial OfficerJeffrey Cohen - MD - Equity Research Conference Call Participants Ross Osborn - Director, Lead Research Analyst - MedTech and DiagnosticsScott Henry - Managing Director & Senior Research Analyst Operator Good day, and thank you for standing by. Welcome to the Nano QX Q1 twenty twenty five Earnings Conf ...

5月19日，南方中证全指医疗保健设备与服务ETF（159877）下跌0.04%，最新净值0.56元，连续4个交 易日下跌，区间累计跌幅1.34%。 来源：金融界 据了解，南方中证全指医疗保健设备与服务ETF成立于2021年10月，基金规模0.91亿元，成立来累计收 益率-44.22%。从持有人结构来看，截至2024年末，南方中证全指医疗保健设备与服务ETF的基金机构 持有0.16亿份，占总份额的10.95%，个人投资者持有0.92亿份，占总份额的63.55%。 公开信息显示，现任基金经理朱恒红先生:中国国籍,北京大学经济学硕士,具有基金从业资格。2016年7 月加入南方基金,历任数量化投资部助理研究员、指数投资部研究员;2019年7月12日至2020年12月25日, 任投资经理;2023年4月13日至2024年5月17日,任南方沪深300ESG基准ETF基金经理;2020年12月25日至 今,任南方策略基金经理;2021年4月23日至今,任南方中证创新药产业ETF基金经理;2021年7月16日至今, 任南方中证香港科技ETF(QDII)基金经理;2021年11月2日至今,任南方中证全指医疗保健ETF基金经 理 ...

5月19日，中欧中证全指医疗保健设备与服务指数发起A（021714）下跌0.04%，最新净值1.05元，连续 4个交易日下跌，区间累计跌幅1.26%。 截止2025年3月31日，中欧中证全指医疗保健设备与服务指数发起A前十持仓占比合计41.48%，分别 为：迈瑞医疗（9.10%）、爱尔眼科（7.77%）、联影医疗（6.36%）、爱美客（3.44%）、惠泰医疗 （3.09%）、新产业（2.86%）、鱼跃医疗（2.63%）、美年健康（2.22%）、九安医疗（2.06%）、山东 药玻（1.95%）。 据了解，中欧中证全指医疗保健设备与服务指数发起A成立于2024年8月，基金规模0.13亿元，成立来累 计收益率4.82%。从持有人结构来看，截至2024年末，中欧中证全指医疗保健设备与服务指数发起A的 基金机构持有0.10亿份，占总份额的91.94%，个人投资者持有0.01亿份，占总份额的8.06%。 来源：金融界 公开信息显示，现任基金经理宋巍巍先生:中国国籍,研究生,硕士。历任中欧基金管理有限公司研究员、 投资经理。现任中欧基金管理有限公司基金经理。2024年1月17日起任中欧中证机器人指数发起式证券 投资基金的基 ...

STERIS (STE) Q4 2025 Earnings Call May 15, 2025 09:00 AM ET Company Participants Julie Winter - Vice President of Investor Relations & Corporate CommunicationsMichael Tokich - Senior VP & CFODaniel Carestio - President, CEO & DirectorPatrick Wood - Managing DirectorMac Etoch - Senior Research Associate Conference Call Participants David Turkaly - Research AnalystMike Matson - Senior Equity Research AnalystMichael Polark - Senior Equity Research AnalystJason Bednar - Senior Research AnalystBrett Fishbin - Vi ...

Financial Data and Key Metrics Changes - First quarter revenue was $5.6 million, a decrease from $9.4 million in the same period in 2024, primarily due to the temporary suspension of sales in France and lower investments in sales and marketing [22][5] - Adjusted net operating loss narrowed by 48% to $5.9 million compared to the prior year, with gross margin expanding to 75% from 73% in the prior year and 45% in the previous quarter [5][22] - Cash and cash equivalents at the end of the first quarter were $20.4 million, providing a runway for achieving FDA approval and profitability [25][12] Business Line Data and Key Metrics Changes - Sales and marketing expenses decreased to $3.6 million from $6.1 million in the same period in 2024, driven by increased operating efficiency [23] - Research and development expenses were reduced to $2.6 million from $5.7 million, primarily due to cost reductions related to the IDISSIPPI trial [23] - General and administrative expenses decreased to $5.2 million from $6.4 million, with adjusted expenses at $3.8 million excluding one-time financing costs [24] Market Data and Key Metrics Changes - The company observed over 40% growth quarter over quarter and year over year in its B2B2C model pilot in clinics in Europe [7] - The company expects revenues to ramp as the year progresses with the expansion of the B2B2C model and enhanced sales team onboarding [8] Company Strategy and Development Direction - The company’s 2025 plan focuses on five pillars: a new commercial plan, gaining FDA approval for the Allurion balloon, achieving profitability for the ex-U.S. business, scaling the AI product platform, and resuming commercialization in France [6][7] - The company aims to combine its program with low doses of GLP-1s to create a new standard of care for obesity, targeting a sustained weight reduction of over 20% while maintaining muscle mass [16][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the efficiency of the new B2B2C model and the potential for significant shareholder value as millions of patients could be treated with the Elerion program [26][27] - The company is optimistic about completing its PMA submission to the FDA by June and is encouraged by the FDA's feedback during the pre-PMA meeting [12][39] Other Important Information - The company has resumed treating patients in France and is in the final phases of updating marketing collateral to reactivate placements [15] - The company does not expect any impact on gross margin from tariffs for the remainder of the year, as most components are manufactured in the U.S. [12][13] Q&A Session Summary Question: Trends in regional markets, especially with the new marketing strategy - Management noted that mature markets for GLP-1s are creating tailwinds, with patients seeking alternatives and the expansion of the direct sales force expected to drive revenue growth [29][30] Question: Timeline and patient enrollment for the GLP-1 trial - Enrollment is expected to begin in the latter half of this year, with a one-year follow-up and a target of at least 75 subjects across multiple sites in Europe [31][32] Question: Design of the trial arms - The trial will focus on validating previous retrospective work with a single arm prospective trial design, leveraging historical data for comparison [33][34] Question: Future gross margin expectations - Management expects margins to remain in the same range as the first quarter, with potential increases as revenues ramp up [35][36] Question: Details on the pre-PMA meeting and next steps - The FDA was receptive to alternative analyses for the control group data, which could strengthen the overall application [39][40] Question: Current adoption of the Elerion program and GLP-1s - There is organic adoption of the combination therapy in the field, with physicians integrating GLP-1s with the Allurion balloon [45][46] Question: Revenue performance cadence for 2025 - Management anticipates steady revenue increases driven by the onboarding of new sales team members and recovery in France [49][50] Question: Expected costs for the prospective study - The prospective trial is not expected to have a material impact on the budget, as existing patient flow and lower costs overseas will be leveraged [51][52] Question: Regulatory strategy regarding expanded labeling - The focus is on the commercial implications of the study, with potential long-term benefits for discussions with regulators and payers [53][54] Question: Procedure growth trends - Procedure volume is stable, with some growth in certain territories, and management expects a recovery in France in the second half of the year [57][58]

对于医药板块2025年全年的投资前景，山西证券研究所副所长、医药大健康组组长邓周宇表示："2025 年板块盈利有望恢复。目前板块PE（市盈率）估值处于历史低位，预计2025年板块会获得相对于大盘 的超额收益。" 在金融投资领域，医药板块向来是机构重点关注和布局的关键赛道之一。在当前市场环境下，券商正通 过重仓买入医药板块相关标的、加大对医药行业的研究分析力度以及扩大在医药领域的投资规模等举 措，全方位、多层次地深化与医药板块的关联。 从券商重仓股的调仓、换股情况来看，Wind资讯数据显示，截至今年一季度末，有25家医药板块 （Wind行业分类包括医药生物、医疗设备与服务）上市公司的前十大流通股股东名单中出现了14家券 商的身影。券商重仓股持仓数量合计为5.08亿股，持仓市值合计为41.18亿元（以一季度末收盘价计算， 下同）。 在持仓变化方面，一季度券商对于医药板块的持仓调整动作频繁，新进持有10只个股，增持3只个股， 减持11只个股。在前述25只医药个股中，未名医药、嘉应制药均被2家券商重仓持有。其中，一季度， 中金公司新进持有嘉应制药805.28万股，东方证券持有嘉应制药股份数量不变；未名医药被申万宏源证 ...

5月9日，塞力医疗今日收盘10.97元，下跌4.94%，最新市净率2.47，总市值20.95亿元。 股东方面，截至2025年3月31日，塞力医疗股东户数46600户，较上次增加16035户，户均持股市值35.28 万元，户均持股数量2.76万股。 最新一期业绩显示，2025年一季报，公司实现营业收入2.87亿元，同比-40.75%；净利润-14320949.69 元，同比-553.66%，销售毛利率23.60%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)2塞力医疗-9.24-10.012.4720.95亿行业平均 36.7828.221.80107.38亿行业中值27.4324.131.3158.16亿1漱玉平民-26.84-24.692.4246.62亿3海王生 物-5.04-5.113.3661.04亿4柳药集团8.268.030.8968.68亿5九州通8.9010.440.99261.70亿6鹭燕医药 9.539.180.9831.74亿7英特集团10.6410.521.1855.27亿8国药股份11.2411.231.28224.69亿9南京医药 11.3811.750.9667.04 ...

Cerus (CERS) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Timothy Lee - Head of Investor RelationsObi Greenman - President and CEOVivek Jayaraman - Chief Operating OfficerKevin Green - VP of Finance & CFOJosh Jennings - Managing DirectorCarol Moore - Senior Vice President of Regulatory Affairs, Quality & ClinicalMatthew Park - Equity Research AssociateVidyun Bais - Equity Research - Vice President Conference Call Participants None - Analyst Operator Good day, ladies and gentlemen. Tha ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002551 证券简称：尚荣医疗 公告编号：2025-023 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 根据中国证监会发布的《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》和深 圳证券交易所颁布的《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第1 号——主板上市公司规范运作》、《深圳证券交易所上市公司自律监管指南第2号——公告格式》等有 关规定，深圳市尚荣医疗股份有限公司（以下简称"公司"或"本公司"），深圳市尚荣医疗股份有限公司 （以下简称"公司"或"本公司"）董事会编制了截至2024年度募集资金存放与实际使用情况的专项报告。 一、募集资金基本情况 根据相关制度，本公司于2019年2月28日与北京银行股份有限公司深圳分行、兴业银行股份有限公司深 圳龙岗支行、中国民生银行股份有限公司深圳上步支行、平安银行股份有限公司深圳分行、中国工商银 行股份有限公司深圳东门支行及保荐机构东兴证券股份有限公司签署《募集资金三方监管协议》。对募 集资金的使用实行严格的审批手 ...